Sanofi Sa · EURONEXT:SAN
Sanofi Sa — Merger or Acquisition (March 2020)
8 slides from Sanofi Sa's merger presentation, Mar 27, 2020
Slide 1: Sanofi expands collaboration with Translate Bio to develop mRNA COVID-19 vaccine
Sanofi expands collaboration with Translate Bio to develop mRNA COVID-19 vaccine March 27, 2020 GettyImages
Slide 2: Forward looking statements
Forward looking statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their under
Slide 3: Agenda
Agenda COVID-19 response David Loew EVP Vaccines, Sanofi Pasteur mRNA technology Ronald Renaud, Jr CEO, Translate Bio Q&A John Shiver SVP R&D, Sanofi Pasteur 3
Slide 4: A unique portfolio to fight the public health emergency
A unique portfolio to fight the public health emergency Sanofi’s multi-pronged approach to combat COVID-19(1) Vaccines 1 BARDA collaboration: Recombinant DNA vaccine mRNA vaccine Antibody 2 Anti IL-6(2) Small molecule 3 hydroxychloroquine (Plaquenil®) BARDA: Biomedical Advanced Research and Developm
Slide 5: Sanofi adding a second vaccine approach for COVID-19
Sanofi adding a second vaccine approach for COVID-19 1 Baculovirus recombinant vaccine approach • Licensed platform(1) • Safety experience(1) + + • • BARDA collaboration Existing large scale manufacturing capacity Cell Protein Adjuvants Culture Antigens 2 Translate Bio mRNA vaccine approach • Differ
Slide 6: Sanofi to capitalize on benefits of mRNA vaccines platform
Sanofi to capitalize on benefits of mRNA vaccines platform Existing agreement to develop Lead mRNA and LNP mRNA vaccines for ✓ ✓ candidates tested across five infectious diseases disease targets Rodent and non-human primate Large scale process studies complete on other ✓ ✓ development in progress fo
Slide 7: Attractive expansion of existing collaboration agreement
Attractive expansion of existing collaboration agreement & • Encouraging preclinical data across multiple infectious disease targets Progress • COVID-19 now added to the 5 vaccines of original agreement from 2018 • Opportunity to accelerate development of mRNA vaccine platform • No upfront fee for a
Slide 8: Q&A session
Q&A session David Loew Ronald Renaud, Jr EVP, Sanofi Pasteur CEO, Translate Bio John Shiver SVP R&D, Sanofi Pasteur 8